Shares of Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of C$14.90 and traded as low as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.
Oncolytics Biotech Trading Down 1.3%
The firm has a fifty day simple moving average of C$14.90 and a 200-day simple moving average of C$14.90. The firm has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
